Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Acromegaly Stories

2009-07-23 09:13:25

Cancer stem-like cells have been implicated in the genesis of a variety of malignant cancers. Research scientists at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute have isolated stem-like cells in benign (pituitary) tumors and used these "mother" cells to generate new tumors in laboratory mice. Targeting the cells of origin is seen as a possible strategy in the fight against malignant and benign tumors.Cells generated from the pituitary tumor cells had the same genetic...

2009-06-26 10:19:26

A multi-center clinical trial led by a Riley Hospital for Children endocrinologist has found that inhaled growth hormone (GH) is well tolerated by children with GH deficiency and that this easy-to-use method can, over a one-week period, safely deliver GH to the blood stream. In addition to having implications for those who need GH, this first pediatric study of administering it through the lungs may also help researchers interested in using this convenient method for effectively delivering...

2009-01-13 17:47:00

- Data show significant 66% reduction in risk of disease progression versus placebo - Sandostatin LAR more than doubled time without tumor growth for a median of 14 months compared to six months on placebo - Results support Sandostatin LAR as first treatment after surgery in certain patients with newly diagnosed neuroendocrine tumors (NETs) EAST HANOVER, N.J., Jan. 13 /PRNewswire/ -- Sandostatin LAR(R) Depot (octreotide acetate suspension for injection) demonstrated antitumor benefit in...

2009-01-05 15:50:00

Company to Host Conference Call January 6, 2009 at 8:30 a.m. EST LEXINGTON, Mass., Jan. 5 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that it has entered into a definitive merger agreement under which Endo Pharmaceuticals Holdings, Inc. will commence a tender offer to acquire 100 percent of the outstanding shares of Indevus for approximately $370 million, or $4.50 per Indevus share, in cash and up to an additional approximately $267 million, or...

2008-10-01 15:00:50

Ambrilia Biopharma Inc. (TSX: AMB) today reported positive 24-week extension Phase III ("Study 302") top line results for its proprietary prolonged-release formulation of octreotide C2L. Overall, the results support the safety of C2L over an additional period of 6 months. In addition, the efficacy as measured by the mean Insulin-like Growth Factor 1 ("IGF-1") and Growth Hormone ("GH") plasma levels is maintained at the same level throughout the study period. It further confirms that...

2008-09-30 09:00:18

LEXINGTON, Mass., Sept. 30 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. today announced the initiation of a Phase III clinical trial of the Company's novel octreotide implant for acromegaly. This trial is designed to test the efficacy, safety and tolerability of the octreotide implant in patients with acromegaly. The implant utilizes the Company's patented HYDRON(R) Polymer Technology to deliver effective levels of octreotide for six months. Octreotide is a synthetic peptide...

2008-08-30 09:00:21

By Asa, Sylvia L * Context.-The sellar region is the site of frequent pathology. The pituitary is affected by a large number of pathologic entities arising from the gland itself and from adjacent anatomical structures including brain, blood vessels, nerves, and meninges. The surgical pathology of this area requires the accurate characterization of primary adenohypophysial tumors, craniopharyngiomas, neurologic neoplasms, germ cell tumors, hematologic malignancies, and metastases as well as...

2008-06-16 15:00:49

Tercica, Inc. (NASDAQ: TRCA) today announced the first results from the Increlex(R) Growth Forum Database (IGFD) Registry in two posters presented at the 90th annual meeting of the Endocrine Society in San Francisco. Increlex(R) (mecasermin (rDNA origin) injection) is currently approved in the United States for the treatment of severe Primary IGF-1 Deficiency. "Data from the IGFD Registry showed that children treated with Increlex(R) at the higher end of the recommended-dose range (greater...